Drug Details
General Information of the Drug (ID: DR8662) | ||||
---|---|---|---|---|
Name |
PFK15
|
|||
Synonyms |
PFK-015; 4382-63-2; PFK15; 1-(Pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one; CHEMBL3105836; (E)-1-pyridin-4-yl-3-quinolin-2-ylprop-2-en-1-one; 1-(4-Pyridinyl)-3-(2-quinolinyl)-2-propen-1-one; PFK 15; PFK015; SCHEMBL2702934; SCHEMBL16534534; AOB4632; SYN5216; BCP10875; EX-A4218; 2649AH; BDBM50445946; s7289; AKOS025287166; ZINC103235314; ACN-050165; CCG-267056; NCGC00386328-09; AC-28651; AS-16574; HY-12204; SW219876-1; A14287; (E)-1-(Pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one; 2314451-67-5
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Investigative | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C17H12N2O
|
|||
PubChem CID | ||||
Canonical SMILES |
C1=CC=C2C(=C1)C=CC(=N2)C=CC(=O)C3=CC=NC=C3
|
|||
InChI |
1S/C17H12N2O/c20-17(14-9-11-18-12-10-14)8-7-15-6-5-13-3-1-2-4-16(13)19-15/h1-12H/b8-7+
|
|||
InChIKey |
UJJUKZPBUMCSJZ-BQYQJAHWSA-N
|
|||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Metformin | Galega officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | PFKFB3 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
OPM-2 | CVCL_1625 | Plasma cell myeloma | Homo sapiens | |||
Experimental
Result(s) |
The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3. |